# BIOX earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/BIOX) · [Earnings tab](https://www.lopjlb.com/stock/BIOX?tab=earnings)

Updated: 2026-09-08T10:14:39

Quarters analyzed: 8

## Cross-quarter narrative

Across the series of BIOX CallCards the company’s financial picture has shifted from modest revenue contraction in Q3 2024 to a deeper, recurring decline through 2025, driven largely by a fragile Argentine market and weather‑related sales shortfalls. Gross margins, however, have trended upward, moving from a flat‑to‑compressed profile in 2024 to a 47% margin in Q1 FY26 as the product mix pivots away from low‑margin Syngenta accruals toward higher‑margin seed royalties. The seed strategy has been overhauled: breeding operations were exited in Q2 2025, new royalty‑based partnerships were forged, and a downstream unwind of HB4 grain sales is on track. HB4 wheat milestones accelerated, with US deregulation delivered and commercialization progressing toward launch. Meanwhile, cash conversion and liquidity pressures have surfaced, reflected in rising net‑debt multiples and a noteholder dispute. SG&A reductions and working‑capital improvements have been realized, but competitive pricing and commodity‑price volatility continue to erode margins. Overall, the narrative moves from a focus on short‑term revenue recovery to a longer‑term, capital‑light royalty model, with mixed signals on demand and persistent macro‑environmental risks.

## Latest CallCard · Q3

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q3:** —
- **2026 Q1:** BIOX Q1 FY26: Revenue -17% to $77.5M, gross margin +650bps to 47%, adj. EBITDA +61% to $13.6M, SG&A savings 50% of annual target; debt dispute with noteholders, net debt/EBITDA 6.8x.
- **2025 Q4:** —
- **2025 Q3:** BIOX Q3 off-season revenue down on missing Syngenta accrual; cash flow improved $40M YoY, debt cut, leverage 4.1x; EPA approved RinoTec, seed business reorganization progressing, HB4 wheat US launch near.
- **2025 Q2:** Revenue fell 24% driven by a weak Argentine market, but gross margin rose to 42% and the company is exiting seed breeding, forming new partnerships and appointing a CCO to pursue a capital‑light, royalty‑focused strategy.
- **2025 Q1:** Bioceres Q1 2025 revenue fell 20% as Argentine rain shortage hit sales, but diversification, recent EPA award and HB4 approvals in Uruguay and Bolivia, plus momentum in the US and Brazil, underpin an optimistic outlook for the rest of the fiscal year.
- **2024 Q4:** Bioceres FY24 revenue $465M, EBITDA $81M record highs; Q4 sales +18%, EBITDA 2x; HB4 wheat US deregulated, HB4 soy guidance cut, 1-2 years for portfolio depth; shifting to conventional seed model for margins.
- **2024 Q3:** BIOX Q3 revenue fell 10% YoY to $84M due to Syngenta payment timing; adjusted EBITDA $21.1M; delayed bio-nutrition sales in Argentina/Brazil expected in Q4; HB4 soy progress in Brazil and bio-insecticide approval support double-digit full-year growth target.

## Theme arcs

- **Revenue trajectory** (deteriorating): Revenue fell 10% YoY in Q3 2024 and continued to drop 20‑24% in 2025 quarters, driven by Argentine market weakness.
- **Gross margin evolution** (improving): Margins rose from flat/compressed in 2024 to 47% in Q1 FY26 as high‑margin seed royalties replace Syngenta accruals.
- **Seed business transformation** (new): Exit from breeding, royalty‑based HB4 model, and downstream unwind initiated in Q2 2025 and progressing.
- **HB4 wheat commercialization** (improving): US deregulation delivered Q4 2024; commercialization on track with launch near Q3 2025.

## Guidance path

2024 Q3:maintained → 2024 Q4:lowered → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:maintained → 2026 Q3:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/BIOX`